According to Section 7 of the SDS, the item should be stored at room temp.
Fortfahren mit
P2116
Pirfenidon
≥97% (HPLC), powder, antifibrotic agent
Synonym(e):
5-Methyl-1-phenyl-2-(1H)-pyridon
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
| Größe/SKU | Verfügbarkeit | Preis |
|---|---|---|
10 mg | Warenkorb auf Verfügbarkeit prüfen | € 115,00 |
50 mg | Warenkorb auf Verfügbarkeit prüfen | € 511,00 |
Über diesen Artikel
Empirische Formel (Hill-System):
C12H11NO
CAS-Nummer:
Molekulargewicht:
185.22
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥97% (HPLC)
Form:
powder
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenProduktname
Pirfenidon, ≥97% (HPLC)
Quality Segment
assay
≥97% (HPLC)
form
powder
solubility
H2O: >10 mg/mL at 60 °C (warming for 30 minutes), DMSO: >20 mg/mL
originator
Shionogi
SMILES string
O=C(C=CC(C)=C1)N1C2=CC=CC=C2
InChI
1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3
InChI key
ISWRGOKTTBVCFA-UHFFFAOYSA-N
General description
Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone) is a synthetic derivative of pyridine.
Application
Pirfenidone has been used:
- as a post-operative eye drop in rabbits to analyse its antifibrotic effect to improve glaucoma filtration surgery
- as an anti-scarring agent to examine whether it affects the foreign body reaction after glaucoma drainage device (GDD) implantation in a rabbit
- to test its antifibrotic potential in primary cultures of human orbital fibroblasts (hOFs)
- as tumor necrosis factor (TNFα) inhibitor to study its effect in hypoxia
Biochem/physiol Actions
Pirfenidone is used to treat idiopathic pulmonary fibrosis (IPF). It helps to decrease the weakening of lung function decline and ameliorate progression-free survival. Pirfenidone can repress the multiplication and contraction of collagen of human tenon′s fibroblasts.
Inhibits collagen production and fibroblast proliferation.
Pirfenidone inhibits collagen production and fibroblast proliferation. It has shown antifibrotic and anti-inflammatory properties in variety of animal models of pulmonary fibrosis, and in clinical trials.
Features and Benefits
This compound was developed by Shionogi. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| description ≥97% (HPLC) | description European Pharmacopoeia (EP) Reference Standard | description ≥98% (HPLC) | description ≥98% (HPLC) |
| form powder | form - | form powder | form powder |
| assay ≥97% (HPLC) | assay - | assay ≥98% (HPLC) | assay ≥98% (HPLC) |
| Quality Level 100 | Quality Level - | Quality Level 100 | Quality Level 100 |
| solubility DMSO: >20 mg/mL, H2O: >10 mg/mL at 60 °C (warming for 30 minutes) | solubility - | solubility DMSO: >20 mg/mL | solubility H2O: >30 mg/mL |
| originator Shionogi | originator - | originator - | originator Teva |
Still not finding the right product?
Explore all of our products under Pirfenidon
Signalwort
Warning
Gefahrencodes
Sicherheitshinweise
Hazard Classifications
Acute Tox. 4 Oral
Lagerklasse
11 - Combustible Solids
Was ist los?
WGK 3
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
PSA (Persönliche Schutzausrüstung)
dust mask type N95 (US), Eyeshields, Gloves
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
-
What are storage conditions after receipt? I am unable to find in the website.
1 answer-
Helpful?
-